Fulgent Genetics (FLGT) Form 144: 1,199-Share Sale via Morgan Stanley

Rhea-AI Filing Summary

Form 144 filed for Fulgent Genetics, Inc. (FLGT) reporting a proposed sale of 1,199 shares of common stock through Morgan Stanley Smith Barney on 08/27/2025 on NASDAQ with an aggregate market value of $25,760.20. The filing shows the shares to be sold were acquired as restricted stock that vested on 02/26/2024 as equity compensation, with 25,350 shares originally issued to the holder on that date. The issuer has 30,609,044 shares outstanding per the notice. The filer disclosed multiple prior open-market sales by the same person in the past three months totaling 3,704 shares with gross proceeds reported on specific dates. The signer certifies no undisclosed material information and acknowledges Rule 144/10b5-1 representations.

Positive

• Insider disclosed sales transparently under Rule 144 with required details and certification of no undisclosed material information
• Securities to be sold were issued as restricted stock for services, indicating they derive from compensation rather than undisclosed purchases
• Proposed sale size is very small relative to the 30,609,044 shares outstanding, suggesting limited market impact

Negative

• Multiple recent sales by the same person in the past three months totaling 3,704 shares could reflect ongoing insider liquidity
• Filing lacks context on whether a 10b5-1 plan is in place (the form references the plan language but does not state a plan adoption date)

Insights

Financial Analyst

TL;DR: Routine insider share sales from vested equity; size is immaterial relative to outstanding shares.

The filing documents a proposed sale of 1,199 shares valued at $25,760 and prior sales totaling 3,704 shares in the trailing three months. These shares were granted as restricted stock that vested 02/26/2024 as equity compensation, indicating they are not open-market purchases but executive compensation liquidity events. At 30.6 million shares outstanding, the proposed sale represents a de minimis percentage of the float and is unlikely to affect valuation materially. The disclosure and Rule 144 certification are standard and reduce regulatory risk of the transaction.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 requirements; multiple recent sales warrant routine monitoring but show no obvious governance red flags.

The filer affirms no material nonpublic information and notes potential 10b5-1 plan representation. The securities originated from restricted stock vesting tied to services rendered, a common compensation mechanism. Multiple small sales by the same individual across May, June and August are disclosed with gross proceeds, which is appropriate transparency. Absent additional context (e.g., departures, related-party transactions), these filings align with typical insider liquidity and compliance practices.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th FL New York NY 10004	1199	25760.2	30609044	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/26/2024	Resticted stock vest	Fulgent Genetics, Inc.			25350	02/26/2024	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	690	14196.92
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	05/27/2025	1183	24271.47
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	06/02/2025	1135	23030.08
Jian Xie C/O Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Monte CA 91731	Common Stock	08/25/2025	696	14965.08

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Fulgent Genetics (FLGT) disclose?

The Form 144 discloses a proposed sale of 1,199 shares of FLGT common stock on 08/27/2025 via Morgan Stanley Smith Barney, valued at $25,760.20, and prior sales totaling 3,704 shares in the past three months.

How were the shares being sold acquired according to the filing?

The shares were acquired as restricted stock that vested on 02/26/2024 and were granted as equity compensation for services rendered.

What is the number of shares outstanding reported in the Form 144 for FLGT?

The filing reports 30,609,044 shares outstanding.

Who is the broker handling the proposed sale in the Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 38th FL, New York, NY.

Does the Form 144 state there is undisclosed material information?

No; the signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.